166 related articles for article (PubMed ID: 27471647)
1. Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors.
Cheng M; Santich BH; Xu H; Ahmed M; Huse M; Cheung NK
Oncoimmunology; 2016 Jun; 5(6):e1168557. PubMed ID: 27471647
[TBL] [Abstract][Full Text] [Related]
2. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
[TBL] [Abstract][Full Text] [Related]
3. Potent antitumor effect of T cells armed with anti-GD2 bispecific antibody.
Nakajima M; Guo HF; Hoseini SS; Suzuki M; Xu H; Cheung NV
Pediatr Blood Cancer; 2021 Jul; 68(7):e28971. PubMed ID: 33844437
[TBL] [Abstract][Full Text] [Related]
4. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.
Cheung NK; Modak S; Lin Y; Guo H; Zanzonico P; Chung J; Zuo Y; Sanderson J; Wilbert S; Theodore LJ; Axworthy DB; Larson SM
J Nucl Med; 2004 May; 45(5):867-77. PubMed ID: 15136638
[TBL] [Abstract][Full Text] [Related]
5. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.
Cheng M; Ahmed M; Xu H; Cheung NK
Int J Cancer; 2015 Jan; 136(2):476-86. PubMed ID: 24895182
[TBL] [Abstract][Full Text] [Related]
6. Generation and characterization of a mouse single-chain antibody fragment specific for disialoganglioside (GD2).
Moutel S; Birkle S; Laurence V; Michon J; Fridman WH; Aubry J; Teillaud JL
Hybridoma; 1997 Aug; 16(4):335-46. PubMed ID: 9309424
[TBL] [Abstract][Full Text] [Related]
7. Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.
Zhao Q; Ahmed M; Guo HF; Cheung IY; Cheung NK
J Biol Chem; 2015 May; 290(21):13017-27. PubMed ID: 25851904
[TBL] [Abstract][Full Text] [Related]
8. Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy.
Laopajon W; Takheaw N; Kotemul K; Pata S; Hongeng S; Kasinrerk W
Explor Target Antitumor Ther; 2023; 4(6):1145-1156. PubMed ID: 38213540
[TBL] [Abstract][Full Text] [Related]
9. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.
Ahmed M; Cheng M; Cheung IY; Cheung NK
Oncoimmunology; 2015 Apr; 4(4):e989776. PubMed ID: 26137406
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.
Hoseini SS; Dobrenkov K; Pankov D; Xu XL; Cheung NK
Oncoimmunology; 2017; 6(6):e1320625. PubMed ID: 28680755
[TBL] [Abstract][Full Text] [Related]
11. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex.
Cheal SM; Xu H; Guo HF; Zanzonico PB; Larson SM; Cheung NK
Mol Cancer Ther; 2014 Jul; 13(7):1803-12. PubMed ID: 24944121
[TBL] [Abstract][Full Text] [Related]
13. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.
Nazha B; Inal C; Owonikoko TK
Front Oncol; 2020; 10():1000. PubMed ID: 32733795
[TBL] [Abstract][Full Text] [Related]
14. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
15. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
[No Abstract] [Full Text] [Related]
16. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo.
Cheung NK; Guo H; Hu J; Tassev DV; Cheung IY
Oncoimmunology; 2012 Jul; 1(4):477-486. PubMed ID: 22754766
[TBL] [Abstract][Full Text] [Related]
17. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
[TBL] [Abstract][Full Text] [Related]
18. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
19. Reducing epitope spread during affinity maturation of an anti-ganglioside GD2 antibody.
Hu J; Huang X; Ling CC; Bundle DR; Cheung NK
J Immunol; 2009 Nov; 183(9):5748-55. PubMed ID: 19812201
[TBL] [Abstract][Full Text] [Related]
20. Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells.
Kalinovsky DV; Kholodenko IV; Kibardin AV; Doronin II; Svirshchevskaya EV; Ryazantsev DY; Konovalova MV; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
